Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Capricor Therapeutics Inc CAPR

Healthcare Biotechnology
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product... see more

Recent & Breaking News (NDAQ:CAPR)

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US

PR Newswire January 25, 2022

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.

GlobeNewswire January 25, 2022

Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19

GlobeNewswire December 13, 2021

Capricor's CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day

GlobeNewswire November 12, 2021

Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2021

Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9

GlobeNewswire November 2, 2021

Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002

GlobeNewswire September 24, 2021

Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences

GlobeNewswire September 22, 2021

Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021

Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021

GlobeNewswire September 2, 2021

Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2021

Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12

GlobeNewswire August 5, 2021

Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock

GlobeNewswire August 4, 2021

Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors

GlobeNewswire July 27, 2021

Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference

GlobeNewswire June 17, 2021

Capricor Therapeutics to Participate in BIO Digital 2021 Conference

GlobeNewswire June 10, 2021

Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

GlobeNewswire May 18, 2021

Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire May 13, 2021

Capricor to Present at the American Society of Gene and Cell Therapy's 24th Annual Meeting

GlobeNewswire May 12, 2021

Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13

GlobeNewswire May 6, 2021